Tonix Pharmaceuticals (NASDAQ:TNXP) Now Covered by StockNews.com

StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research report sent to investors on Wednesday morning. The brokerage issued a hold rating on the stock.

Tonix Pharmaceuticals Price Performance

TNXP stock opened at $0.33 on Wednesday. The company has a market capitalization of $61.64 million, a P/E ratio of -0.01 and a beta of 2.23. The company has a fifty day moving average price of $0.23 and a 200-day moving average price of $0.37. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. Tonix Pharmaceuticals has a 52-week low of $0.12 and a 52-week high of $14.08.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The business had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. As a group, equities analysts expect that Tonix Pharmaceuticals will post -17.63 EPS for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.